Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR: Galantamine is a nicotinic APL
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Galantamine (Reminyl) is a novel drug treatment for mild to moderate Alzheimer's disease (AD). Originally established as a reversible inhibitor of the acetylcholine-degrading enzyme acetylcholinesterase (AChE), galantamine also acts as an allosterically potentiating ligand (APL) on nicotinic acetylcholine receptors (nAChR). Having previously established this second mode of action on nAChRs from murine brain, we demonstrate here the same action of galantamine on the most abundant nAChR in the human brain, the alpha4/beta2 subtype. This nAChR-sensitizing action is not a common property of all, or most, AChE inhibitors, as is shown by the absence of this effect for other therapeutically applied AChE inhibitors including tacrine, metrifonate, rivastigmine and donepezil. The possible benefits for therapy of AD of an APL action on nicotinic receptors is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alkondon, M., Pereira, E. F. R., Eisenberg, H. M., & Albuquerque, E. X. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00066.2000 · Cited by 248 · cited 1×
“From electrophysiological studies of human cerebral cortical interneurons (12), a4/b2 nAChRs are located on the somatodendritic regions of human interneurons and, as demonstrated by their ability to modulate GABA release, they can also affect presynaptic activity.”
BackgroundSelf-citation
Cited by
Mammalian nicotinic acetylcholine receptors: from structure to function
Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009) · Physiological Reviews · doi:10.1152/physrev.00015.2008 · Cited by 1,724
Self-citationDrugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel, R. (2009) · Physiological Reviews · doi:10.1152/physrev.00013.2008 · Cited by 634
Nicotinic acetylcholine receptors: from structure to brain function
Hogg, R. C., Raggenbass, M., & Bertrand, D. (2003) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/s10254-003-0005-1 · Cited by 528
Metadata
- Authors
- Samochocki, M., Zerlin, M., Jostock, R., Groot Kormelink, P. J., Luyten, W. H. M. L., Albuquerque, E. X., & Maelicke, A.
- Venue
- Acta Neurologica Scandinavica
- Publisher
- Wiley
- Published
- 2000-12
- Volume
- 102
- Pages
- 68-73
- ISSN
- 0001-6314 (ISSN-L)
- OpenAlex
- W1955195137
- Cited by
- 149
- References
- 1
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR: Galantamine is a nicotinic APL. https://app.cochat.ai/papers/10.1034/j.1600-0404.2000.00310.x
- The paper
- Samochocki, M., Zerlin, M., Jostock, R., Groot Kormelink, P. J., Luyten, W. H. M. L., Albuquerque, E. X., & Maelicke, A. (2000). Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR: Galantamine is a nicotinic APL. Acta Neurologica Scandinavica. https://doi.org/10.1034/j.1600-0404.2000.00310.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.